RTP-based BioAesthetics has announced an additional clinical trial of its NACgraft, a biologically derived allograft for patients needing nipple reconstruction, to investigate its use of in male and female patients.
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)SAN DIEGO (BUSINESS WIRE) Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomav.